Chiesi Highlights Innovationsโ in Respiratory Care โฃat Recent Event
Chiesi recently participated in an event โคshowcasing advancementsโ in respiratory care, โwith a strong focus โคon biomarkers and digitalโ technologies.โ A key session, “Transform Asthma Management,” explored improvingโข long-term disease control and reducing exacerbations through combining โextrafine therapyโ with evidence-based practices, specifically targetingโ the small airway and identifyingโ treatable features.
Beyond โขsymposia,โ Chiesi hosted six live sessions at its stand, dedicated โขto discussions around innovation, patient experience, and sustainability โขin respiratoryโข treatment.The company also collaborated with academic institutions and scientific societies on twoโฃ joint sessions, addressing the management โฃof bronchiectasisโค and theโฃ importance of optimal inhalation techniques for therapeutic efficacy.
Chiesi โpresentedโฃ over 50 abstracts stemming from its own research and collaborative studies, โsolidifying its position as a leader in respiratory research. Notable advancements included the โdevelopment of precision medicine tools utilizing precision pulmonaryโ cuts โค(PCLS) and artificial intelligence (AI)-enhanced imaging, aiming to optimize treatment selection and enable earlier diagnosis of lung alterations.
The company also shared data on biomarkers usedโข to identify asthma exacerbation phenotypes โand airway remodeling,leveraging advanced image and transcriptomic โฃtechniques. Digital โฃhealth solutions were also introduced, including Epro โ(electronicallyโ reported patient outcomes) and automaticโฃ learning models for asthmaโข diagnosis and monitoring, facilitatingโค personalized medicine and remote patient management.
Michelle Soriano, Executive Vice President from Air Franchise In Chies, emphasized the need forโข a holistic approachโฃ to respiratory care, extendingโข beyond new treatments to โencompass equitableโ access to diagnosis, proper inhalerโ selection,โค and optimized therapeutic โคstrategies.
Chiesi’s commitment to sustainability โis underscored by its status as a Certified B Corp asโ 2019. Theโ company aims to โachieve greenhouse gasโ emission neutrality by 2035,integrating scientific innovation with corporate responsibility.
With over 90 yearsโ of experience and a presenceโ in 31 countries, Chiesi is โestablishing itself as a pivotal force inโ the evolution ofโค respiratory medicine, โขcombining cutting-edge science,โข digital technologies, and โenvironmental responsibility to enhance โคthe โlives of patients withโฃ chronic pulmonary diseases.